Literature DB >> 11759073

Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.

A Märten1, C Ziske, B Schöttker, S Renoth, S Weineck, P Buttgereit, F Schakowski, A von Rücker, T Sauerbruch, I G Schmidt-Wolf.   

Abstract

Dendritic cells (DCs) are major antigen-presenting cells. They are capable of capturing and processing tumor antigens, expressing lymphocyte costimulatory molecules, and secreting cytokines to initiate immune responses. Here, the authors tested the effect of cytokine-induced killer (CIK) cells, a population that includes CD3+CD56+ cells (natural killer T cells), with regard to their capacity to immunomodulate DCs. Cytokine-induced killer cells were cocultured with autologous DCs generated from peripheral blood mononuclear cells. Expression of markers typical for both populations was measured using flow cytometry, and secretion of interleukin (IL)-12 was determined using enzyme-linked immunosorbent assays. Cytotoxicity assays were performed to investigate the role of IL-12 and the importance of cell-cell interactions. Considering this, receptors for IL-12 and CD40 were blocked and cocultures were performed with cell culture inserts. Coculture of CIK cells led to a significant increase of DC-specific, costimulatory, and antigen-presenting molecules in DC cultures. In addition, coculture resulted in a dramatically increase of IL-12 secretion by DCs and to a significant increase in cytotoxic activity of CIK cells toward carcinoma cells. Blockage of IL-12 uptake decreased the cytolytic activity of CIK cells. Cytokine secretion was shown to be important for activation of CIK cells, and also cellular interactions between DCs and effector cells caused a higher cytolytic capacity. Interactions between DCs and CIK cells caused changes in the surface molecule expression of both populations, led to an increase of IL-12 secretion, and rendered an improved cytotoxic activity. The natural killer T cell subpopulation seems to be responsible for this effect. Therefore, coculture of DCs with CIK cells may have a major impact on immunotherapeutic protocols for patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11759073     DOI: 10.1097/00002371-200111000-00007

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  31 in total

Review 1.  Review of Chinese clinical trials on CIK cell treatment for malignancies.

Authors:  Xiao-Dong Li; Bin Xu; Jun Wu; Mei Ji; Bei-Hua Xu; Jing-Ting Jiang; Chang-Ping Wu
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.

Authors:  Tao Lin; Chun Song; Dong-Yu Chuo; Hao Zhang; Jian Zhao
Journal:  Tumour Biol       Date:  2015-10-24

3.  Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.

Authors:  Xiaosan Su; Lei Zhang; Liangkun Jin; Junsong Ye; Zheng Guan; Rui Chen
Journal:  J Clin Immunol       Date:  2010-06-15       Impact factor: 8.317

4.  A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients.

Authors:  Runbo Zhong; Baohui Han; Hua Zhong
Journal:  Tumour Biol       Date:  2013-09-05

5.  Cytokine-induced killer cells combined with dendritic cells inhibited liver cancer cells.

Authors:  Qi-Ying Li; Yang Shi; De-Hong Huang; Tao Yang; Jiang-Hong Wang; Guo-He Yan; Hong-Yu Wang; Xian-Jun Tang; Chun-Yan Xiao; Wen-Jun Zhang; Man Zhang; Li Wang; Yi Gong; Wei Yang; Xian-Yu Wu; Ying Xiang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites.

Authors:  Yue-Qin Ai; Kai Cai; Jian-Hua Hu; Long-Wei Jiang; Yan-Rong Gao; Hua Zhao; Shao-Chang Jia
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 7.  Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Authors:  Hailing Liu; Yunbao Pan; Shan Meng; Wanggang Zhang; Fuling Zhou
Journal:  Clin Exp Med       Date:  2017-01-24       Impact factor: 3.984

Review 8.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

9.  Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect.

Authors:  Xu-Cang Wei; Di-Di Yang; Xiu-Rui Han; Yu-An Zhao; Yan-Chun Li; Li-Jie Zhang; Jiu-Ju Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

Authors:  Ming Shi; Bing Zhang; Zi-Rong Tang; Zhou-Yun Lei; Hui-Fen Wang; Yong-Yi Feng; Zhen-Ping Fan; Dong-Ping Xu; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.